Why the study?
Pulmonary embolism diagnosis can be challenging, particularly in patients with respiratory comorbidities, motivating the need to evaluate novel diagnostic biomarkers beyond D-dimers to enhance prompt and accurate diagnosis.
What is the evidence for using novel biomarkers beyond D-dimers in the diagnosis and risk stratification of pulmonary embolism?
What is the evidence for using novel biomarkers beyond D-dimers in the diagnosis and risk stratification of pulmonary embolism?
Novel biomarkers such as factor VIII, Ischemia Modified Albumin, and microRNAs are being investigated to enhance the diagnosis and predict recurrence risk in pulmonary embolism beyond standard D-dimer testing.
Highlights diagnostic challenges in comorbid PE patients; leaves open validation of novel algorithms in prospective trials.
Pulmonary embolism (PE) is a rather common cardiovascular disorder constituting one of the major manifestations of venous thromboembolism (VTE). It is associated with high mortality and substantial recurrence rates, and its diagnosis may be challenging, especially in patients with respiratory comorbidities. Therefore, providing a prompt and accurate diagnosis for PE through developing highly sensitive and specific diagnostic algorithms would be of paramount importance. There is sound evidence supporting the use of biomarkers to enhance the diagnosis and predict the recurrence risk in patients with PE. Therefore, several novel biomarkers, such as factor VIII, Ischemia Modified Albumin, and fibrinogen, as well as several MicroRNAs and microparticles, have been investigated for the diagnosis of this clinical entity. The present review targets to comprehensively present the literature regarding the novel diagnostic biomarkers for PE, as well as to discuss the evidence for their use in daily routine.
No takes yet. Share an insight, caveat, or question.
Gkana et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: